KaloCyte Overview

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Latest Deal Amount
  • $5M

  • Investors
  • 17

KaloCyte General Information

Description

Developer of a red blood cell substitute designed to support oxygen delivery in trauma care settings. The company offers context-dependent oxygen release with reduced vasoconstriction and minimized methemoglobin formation, enabling emergency physicians, military medical teams, and critical care providers to treat traumatic hemorrhage when banked blood is unavailable or unsuitable.

Contact Information

Website
www.kalocyte.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4 North Martin Luther King Junior Boulevard
  • Suite 300
  • Baltimore, MD 21201
  • United States
+1 (410)
Primary Industry
Biotechnology
Vertical(s)
Nanotechnology, Life Sciences
Corporate Office
  • 4 North Martin Luther King Junior Boulevard
  • Suite 300
  • Baltimore, MD 21201
  • United States
+1 (410)

KaloCyte Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KaloCyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
21. Later Stage VC 02-Jun-2025 $5M In Progress Pre-Clinical Trials
20. Secondary Transaction - Private 01-Apr-2026 Completed Pre-Clinical Trials
19. Later Stage VC 28-Oct-2025 Completed Pre-Clinical Trials
18. Accelerator/Incubator 28-Jan-2025 Completed Pre-Clinical Trials
17. Angel (individual) 29-Apr-2024 Completed Clinical Trials - General
16. Grant 15-Apr-2024 Completed Clinical Trials - General
15. Grant 22-Aug-2023 Completed Pre-Clinical Trials
14. Later Stage VC (Series A) 17-Jul-2023 Completed Pre-Clinical Trials
13. Grant 23-Jan-2023 $3.6M $4.8M Completed Pre-Clinical Trials
12. Later Stage VC 20-Jul-2022 $4.8M Completed Pre-Clinical Trials
To view KaloCyte’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

KaloCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a red blood cell substitute designed to support oxygen delivery in trauma care settings. The company offers
Biotechnology
Baltimore, MD
23 As of 2026

Natick, MA
 

Souderton, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

KaloCyte Competitors (4)

One of KaloCyte’s 4 competitors is VirTech Bio, a Venture Capital-Backed company based in Natick, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
VirTech Bio Venture Capital-Backed Natick, MA
HbO2 Therapeutics Venture Capital-Backed Souderton, PA
Hemarina Venture Capital-Backed France
NuvOx Therapeutics Venture Capital-Backed Tucson, AZ
To view KaloCyte’s complete competitors history, request access »

KaloCyte Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

KaloCyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260076917-A1 Composition and process for a lipid nano-particle delivery of oxygen and vital metabolic compounds for hemorrhagic shock Pending 16-Aug-2024
WO-2026039837-A1 Composition and process for a lipid nano-particle delivery of oxygen and vital metabolic compounds for hemorrhagic shock Pending 16-Aug-2024
AU-2022232631-A1 Compositions and methods for removing bio-synthetic nano-particles from bodily fluids Pending 11-Mar-2021
CA-3210619-A1 Compositions and methods for removing bio-synthetic nano-particles from bodily fluids Pending 11-Mar-2021
EP-4304654-A1 Compositions and methods for removing bio-synthetic nano-particles from bodily fluids Pending 11-Mar-2021 C07F9/091
To view KaloCyte’s complete patent history, request access »

KaloCyte Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KaloCyte Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Johnson & Johnson Innovation - JLABS Accelerator/Incubator
United States Department of War Government
Comcast RISE Other
Ferocity Capital Venture Capital Minority
TEDCO Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

KaloCyte FAQs

  • Where is KaloCyte headquartered?

    KaloCyte is headquartered in Baltimore, MD.

  • What is the size of KaloCyte?

    KaloCyte has 23 total employees.

  • What industry is KaloCyte in?

    KaloCyte’s primary industry is Biotechnology.

  • Is KaloCyte a private or public company?

    KaloCyte is a Private company.

  • What is the current valuation of KaloCyte?

    The current valuation of KaloCyte is .

  • What is KaloCyte’s current revenue?

    The current revenue for KaloCyte is .

  • How much funding has KaloCyte raised over time?

    KaloCyte has raised $5.65M.

  • Who are KaloCyte’s investors?

    Johnson & Johnson Innovation - JLABS, United States Department of War, Comcast RISE, Ferocity Capital, and TEDCO are 5 of 17 investors who have invested in KaloCyte.

  • Who are KaloCyte’s competitors?

    VirTech Bio, HbO2 Therapeutics, Hemarina, and NuvOx Therapeutics are competitors of KaloCyte.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process